Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK pathway, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zeren
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Patterson Medical, ... (Nasdaq: PDCO ), is now an independent ... acquisition of Patterson Medical by Madison Dearborn Partners ... its name for a transition period before rebranding ... and sports medicine products.  With the focused resources ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Latanoprost Market Investigation Report 2015-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... Diversifies Revenue Streams and Boosts Scale in Existing Generics ... Expected to be Immediately Accretive to Adjusted Diluted Earnings per ... Company Reiterates Full-Year 2010 Financial Guidance ... today that it has entered into a definitive agreement to ...
... (Nasdaq: DCTH ) announced today that management will ... Tuesday, October 5, 2010 at 8:45 a.m. ET in New ... an overview of the Company,s business strategy and recent corporate ... only. Delcath will offer a live audio webcast of its ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 2Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 3Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 4Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 5Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 6Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 7Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 8Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion 9Delcath to Present at the William Blair Emerging Growth Stock Conference 2
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk for ... posted an article on the new research. Click here to read it now. ... French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the workers ...
(Date:8/30/2015)... , ... August 30, 2015 , ... ... has been promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould ... a proven professional, focused on your goals. Kathleen graduated from Florida State ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , ... 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park ...
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available on ... was required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations ... of the item’s selling price.” , With competitive pricing in the e-commerce market for ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN ... announced that it will be devoting an entire short segment to the subject of ... around the globe on a daily basis, but recent advancements in medical science may ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Health Foundation,s Annual Salute to Service Award , ... second consecutive year, Jim Kerwin of Oxford Communications ( ... announce that Oxford Communications will be the primary sponsor ... Award Luncheon on June 17th and Celebrity Golf Tournament ...
... Agency hopes to better explain its decisions to regain lost ... Food and Drug Administration, an agency long criticized for not ... it has created a task force to study how to ... to try and figure out how to make FDA and ...
... LAUDERDALE, Fla., June 2 LifeSync Corporation, the ... announced that Florida Hospital in Orlando has completed ... its Cardiovascular Institute for patients undergoing cardiovascular surgery. ... in the Florida Hospital System, houses the Florida ...
... This ... health care advocacy but it does little to help the public, says Erika Schwartz, MD ... (PRWEB) June 2, 2009 -- This week,s ... care advocacy but it does little to help the public, says Erika Schwartz, MD in her ...
... PEMBROKE, Bermuda, June 2 Darwin ... Company,Holdings, Ltd (NYSE: AWH ), today ... Manager, will be participating in a,panel at the American ... 3, 2009. The roundtable is titled "Market, Claims,and Healthcare ...
... , MILLERSVILLE, Md., June 2 Travel Advantage Network ... spring morning to support the National Alliance for Research ... kilometers of it. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090602/DC26325 ) ... support the charity by completing a 2.5K sponsored walk at ...
Cached Medicine News:Health News:Jim Kerwin Announces Oxford Communications To Be the Title Sponsor of Bermuda Health Foundation Salute for the Second Year 2Health News:FDA to Study Ways to Be More Open With Public 2Health News:FDA to Study Ways to Be More Open With Public 3Health News:Florida Hospital Cardiovascular Institute Completes House-Wide Implementation of the LifeSync(R) Wireless ECG System 2Health News:Florida Hospital Cardiovascular Institute Completes House-Wide Implementation of the LifeSync(R) Wireless ECG System 3Health News:Dr Erika Says Newsweek's Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 2Health News:Darwin's Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable, June 3, 2009 2Health News:Darwin's Kim Lloyd to Speak on Panel at American Hospital Association Solutions Roundtable, June 3, 2009 3Health News:A Little Bit of Leg Work Goes a Long Way for Travel Advantage Network and Mental Health Charity 2
... for Western Blot analysis ... Western Blot Analyzer for many applications including ... presence of infectious diseases such as viruses ... accurate screening of allergies and other application ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Store 200 to 350 Liters of ... Storage and Distribution of Purified Water,Millipores compact ... to store 200 to 350 liters of ... systems, and to maintain consistent purity of ...
... Liters of pure water, Complete, Compact Systems ... Water,Millipores compact S.D.S. Storage and Distribution Systems ... liters of purified water produced by Elix ... purity of stored water, provide effective protection ...
Medicine Products: